- Home
- CKPT vs FLL Comparison
CKPT vs FLL Comparison
Compare CKPT & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- FLL
- Stock Information
- Founded
- CKPT 2014
- FLL 1987
- Country
- CKPT United States
- FLL United States
- Employees
- CKPT N/A
- FLL 1822
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- CKPT Health Care
- FLL Consumer Discretionary
- Exchange
- CKPT Nasdaq
- FLL Nasdaq
- Market Cap
- CKPT 172.4M
- FLL 184.6M
- IPO Year
- CKPT 2017
- FLL 1993
- Fundamental
- Price
- CKPT $3.13
- FLL $5.33
- Analyst Decision
- CKPT Strong Buy
- FLL Strong Buy
- Analyst Count
- CKPT 3
- FLL 4
- Target Price
- CKPT $12.00
- FLL $6.50
- AVG Volume (30 Days)
- CKPT 753.4K
- FLL 156.7K
- Earning Date
- CKPT 03-21-2025
- FLL 03-06-2025
- Dividend Yield
- CKPT N/A
- FLL N/A
- EPS Growth
- CKPT N/A
- FLL N/A
- EPS
- CKPT N/A
- FLL N/A
- Revenue
- CKPT $47,000.00
- FLL $279,132,000.00
- Revenue This Year
- CKPT N/A
- FLL $23.82
- Revenue Next Year
- CKPT $300,658.78
- FLL $11.07
- P/E Ratio
- CKPT N/A
- FLL N/A
- Revenue Growth
- CKPT N/A
- FLL 28.57
- 52 Week Low
- CKPT $1.38
- FLL $3.77
- 52 Week High
- CKPT $4.50
- FLL $5.94
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- FLL 60.18
- Support Level
- CKPT $3.10
- FLL $5.10
- Resistance Level
- CKPT $3.43
- FLL $5.56
- Average True Range (ATR)
- CKPT 0.26
- FLL 0.19
- MACD
- CKPT 0.00
- FLL -0.02
- Stochastic Oscillator
- CKPT 33.03
- FLL 58.18
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.